Senhwa Biosciences, Inc. (TPEX:6492)

Market Cap	4.74B +26.0%
Revenue (ttm)	1.08M +8.0%
Net Income	-263.96M
EPS	-2.96
Shares Out	89.19M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,000
Average Volume	1,330,331
Open	51.70
Previous Close	53.10
Day's Range	51.20 - 53.50
52-Week Range	28.45 - 66.50
Beta	1.35
RSI	50.79
Earnings Date	Mar 16, 2026

About Senhwa Biosciences

Senhwa Biosciences, Inc., a drug development company, engages in the development of new drugs and targeted agents. The company develops CX-5461, a phase I, open-label, dose escalation, safety, pharmacokinetic, and pharmacodynamics study of intravenously administered CX-5461 in patients with advanced hematologic malignancies; CX-5461, which is in a phase I study for solid tumors; CX-5461 that is in a phase Ib expansion study of CX-5461 in patients with solid tumors and BRCA2 and /or PALB2 mutation; and CX-5461, which is in Phase I trial of pidna...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2012
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6492

Financial Performance

In 2024, Senhwa Biosciences's revenue was 1.00 million, a change of 0.00% compared to the previous year's 1.00 million. Losses were -293.75 million, -0.86% less than in 2023.